Valuation: Lipocine Inc.

Market Cap 1.78Cr 1.56Cr 1.46Cr 1.33Cr 2.51Cr 170.24Cr 2.51Cr 18Cr 6.77Cr 87Cr 6.69Cr 6.54Cr 280.26Cr P/E 2026 *
-1.4x
P/E 2027 * -1.61x
Enterprise Value 1.78Cr 1.56Cr 1.46Cr 1.33Cr 2.51Cr 170.24Cr 2.51Cr 18Cr 6.77Cr 87Cr 6.69Cr 6.54Cr 280.26Cr EV / Sales 2026 *
28.2x
EV / Sales 2027 * 23.9x
Free-Float
95.49%
Yield 2026 *
-
Yield 2027 * -
1 day+0.69%
1 week-1.14%
Current month-3.57%
1 month+3.35%
3 months-5.68%
6 months-69.79%
Current year-73.10%
1 week 2.1
Extreme 2.1
2.25
1 month 2.05
Extreme 2.0501
2.5
Current year 1.81
Extreme 1.81
12.37
1 year 1.81
Extreme 1.81
12.37
3 years 1.81
Extreme 1.81
12.37
5 years 1.81
Extreme 1.81
32.13
10 years 1.81
Extreme 1.81
100.3
Manager TitleAgeSince
Chief Executive Officer 69 01/01/1997
Chief Tech/Sci/R&D Officer 56 01/12/2022
Chief Tech/Sci/R&D Officer 68 -
Director TitleAgeSince
Chairman 69 08/01/2014
Director/Board Member 58 01/01/2003
Chairman 73 20/04/2026
Date Insider Type Main position Quantity % Market Cap. Importance
03/08/26 Free

Director

2,000 0.0243%
03/06/26 Free

Director

1,764 0.0214%
03/06/26 Free

Chairman

1,764 0.0214%
Change 5-day change 1-year change 3-year change Capi.($)
-3.57%-1.14%-24.48%-35.33% 1.78Cr
-0.07%+7.14%+53.95%+111.00% 7.43TCr
-0.37%+0.45%+35.95%+78.63% 6.12TCr
+0.28%+5.73%+33.67%+20.82% 2.75TCr
-0.15%+0.75%-16.69%+361.67% 2.64TCr
+2.93%+4.32%+2.18%-3.60% 2.53TCr
+1.45%+4.16%+26.19%-8.65% 2.08TCr
-1.47%+4.86%-5.94%+519.63% 1.49TCr
+0.87%-3.73%+159.95%+327.53% 1.52TCr
+1.63%+2.20%+46.92%+170.72% 1.44TCr
Average +0.58%+2.74%+31.17%+154.24% 2.8TCr
Weighted average by Cap. +0.34%+3.44%+36.80%+135.98%

Financials

2026 *2027 *
Net sales 6L 6L 5L 5L 9L 6.03Cr 9L 62.23L 24.01L 3.08Cr 23.71L 23.19L 9.93Cr 7L 7L 6L 6L 10.48L 7.12Cr 10.48L 73.44L 28.34L 3.64Cr 27.98L 27.36L 12Cr
Net income -1.26Cr -1.1Cr -1.04Cr -94.76L -1.78Cr -120.86Cr -1.78Cr -12Cr -4.81Cr -62Cr -4.75Cr -4.64Cr -198.97Cr -1.62Cr -1.42Cr -1.33Cr -1.22Cr -2.28Cr -155.03Cr -2.28Cr -16Cr -6.17Cr -79Cr -6.09Cr -5.96Cr -255.24Cr
Net Debt - -
Logo Lipocine Inc.
Lipocine Inc. is a biopharmaceutical company leveraging its proprietary technology platform to enable effective oral delivery of therapeutics. The Company’s clinical development candidates include: LPCN 1154, oral brexanolone, for the treatment of postpartum depression, LPCN 2101, for the treatment of epilepsy, LPCN 2203, an oral candidate targeted for the management of essential tremor, LPCN 2401, an oral proprietary anabolic androgen receptor agonist for improved body composition in obesity management, and LPCN 1148, for the management of decompensated cirrhosis. It is also developing LPCN 1107, for the prevention of preterm birth, LPCN 1154, for rapid relief of postpartum depression, and LPCN 1144, for the treatment of metabolic dysfunction-associated steatohepatitis. Its product candidate, TLANDO, is a novel oral prodrug of testosterone containing testosterone undecanoate developed by the Company.
Employees
14
Date Price Change Volume
22/26/22 $2.160 -3.57% 64,403
21/26/21 $2.240 +1.36% 16,716
18/26/18 $2.210 -0.45% 48,485
17/26/17 $2.220 +2.78% 43,866
16/26/16 $2.160 -1.14% 64,031
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
-
Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
2
Last Close Price
2.160USD
Average target price
5.000USD
Spread / Average Target
+131.48%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. LPCN Stock
-40%: Exceptional extension
d
:
:
SEIZE THE OFFER!